

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

北斗嘉藥業股份有限公司

BAYTACARE PHARMACEUTICAL CO., LTD.*

(a joint stock limited company incorporated in the People's Republic of China)

(Stock Code: 8197)

UPDATE ON THE LISTING STATUS AND SUSPENSION OF TRADING

This announcement is made by Baytacare Pharmaceutical Co., Ltd (the “**Company**”) pursuant to the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

UPDATE ON THE LISTING STATUS

References are made to the announcements (the “**Announcements**”) of the Company dated 16 September 2018 and 18 September 2018. Terms defined in the Announcements shall have the same meaning herein unless otherwise defined or the context otherwise required.

As mentioned in the Announcement, the Company has received the Letter, that the Stock Exchange has decided to suspend trading in the Shares under Rule 9.04 of the GEM Listing Rules and proceed with cancellation of the Company's listing under Rule 9.14 of the GEM Listing Rules (the “**Decision**”). Under Rule 4.06(1) of the GEM Listing Rules, the Company has the right to have the Decision referred to the GEM Listing Committee for review. The Company may request that the Decision be reviewed by the GEM Listing Committee on or before 26 September 2018.

The Board wishes to inform Shareholders of the Company that the Company did not lodge a request for the Decision be referred to the GEM Listing Committee of the Stock Exchange pursuant to Chapter 4 of the GEM Listing Rules for review by the date of this announcement.

SUSPENSION OF TRADING

Based on the above, at the request of the Company, trading in the shares of the Company will be suspended with effect from 9:00 a.m. on 27 September 2018.

Further announcement(s) will be made by the Company as and when appropriate and in accordance with the requirements of the GEM Listing Rules.

Shareholders who have any queries about the implications of the Stock Exchange's notice of proceeding to cancel the Company's listing are advised to obtain appropriate professional advice.

By Order of the Board
Baytacare Pharmaceutical Co., Ltd. *
Executive Director
Cui Bingyan

Beijing, People's Republic of China, 26 September 2018

As at the date of this announcement, the executive Directors are Cui Bingyan, Fang Yao and Guo Aiqun; the non-executive Directors are Shi Peng and Cao Yang; and the independent non-executive Directors are Hui Lai Yam, Gao Zhikai and Chen Youfang.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Company Announcements" page of the website of GEM at www.hkgem.com for at least 7 days from the date of the publication and the Company's website at www.baytacare.com from the date of this announcement.

* *for identification purposes only*